• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,825.26
  • 0.07 %
  • $30.65
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,166.43
  • -0.22 %
  • -$17.81
  • IXIC
  • $18,282.33
  • 0.56 %
  • $102.35
IDEAYA Biosciences, Inc. (IDYA) Stock Price, News & Analysis

IDEAYA Biosciences, Inc. (IDYA) Stock Price, News & Analysis

Currency in USD Disclaimer

$29.51

-$0.49

(-1.63%)

Day's range
$29.36
Day's range
$29.51
50-day range
$27.52
Day's range
$40.74
  • Country: US
  • ISIN: US45166A1025
52 wk range
$27.52
Day's range
$47.74


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 25.29
  • Piotroski Score 2.00
  • Grade Outperform
  • Symbol (IDYA)
  • Company IDEAYA Biosciences, Inc.
  • Price $29.51
  • Changes Percentage (-1.63%)
  • Change -$0.49
  • Day Low $29.36
  • Day High $29.51
  • Year High $47.74

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/18/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $53.00
  • High Stock Price Target $66.00
  • Low Stock Price Target $18.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.00
  • Trailing P/E Ratio -19
  • Forward P/E Ratio -19
  • P/E Growth -19
  • Net Income $-112,961,000

Income Statement

Quarterly

Annual

Latest News of IDYA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.